<DOC>
	<DOCNO>NCT00728312</DOCNO>
	<brief_summary>The purpose study test whether treatment Aripiprazole lead reduction methamphetamine craving use patient diagnose methamphetamine dependence . Patients present Omaha VA Medical Center treatment methamphetamine dependence , meet inclusion criterion study invited participate . Participation study last approximately 14 week .</brief_summary>
	<brief_title>Aripiprazole Methamphetamine Dependence : Double Blind Placebo Trial</brief_title>
	<detailed_description>Methamphetamine abuse dependence become major health problem . The lifetime prevalence rate disorder may high 2-3 % lead significant medical , psychiatric , dental problem increase morbidity mortality . Methamphetamine abuse pattern use lead problem one area life . Methamphetamine dependence severe disorder , often involve biological adaptation effect methamphetamine , tolerance physical dependence methamphetamine , loss control use ( noted several fail attempt quit , preoccupation next high , etc . ) , maladaptive consequence secondary excessive use , include medical , legal , social consequence methamphetamine intake . The lack FDA-approved medication methamphetamine dependence result increased demand research area pharmacotherapy disorder . While medication study exploratory fashion , still great need research area . The purpose study examine efficacy aripiprazole ( relatively low dose 5-15 mg per day ) , compare placebo prospective , double blind study participant methamphetamine dependence , reduce use crave methamphetamine . We expect aripiprazole significantly reduce use methamphetamine measure change proportion participant 's methamphetamine-free week . Secondary outcome include ; urine quantitative methamphetamine , self-report methamphetamine use ( measured Time Line Follow Back Scale - TLFB , Brief Substance Craving Scale -BSCS ) , cave use substance course 12 week active treatment portion trial . A secondary goal study test efficacy Interactive Voice Response ( IVR ) technology gather data participant , correlation data methamphetamine substance use , crave , medication adherence collect weekly visit . Patient 's mood anxiety measure course study use Hamilton Anxiety Scale ( HAM-A ) , Hamilton Depression Scale ( HAM-D ) , Quality Life Index ( QOLI ) . Safety measure include Abnormal Involuntary Movement Scale ( AIMS ) , Side Effects Checklist ( SEC ) , Barnes Akathisia scale , Fasting Blood Glucose Monitoring , patient weight monitoring .</detailed_description>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Veterans , age 19 65 , willing able provide inform consent Primary diagnosis methamphetamine dependence determine Structured Clinical Interview DSMIV ( SCIDII ) . They must current dependence substance alcohol , cocaine , opiates , marijuana . However , abuse drug allow study . Within 30 day last use methamphetamine . Must use least month past three month enrollment . Present without current intoxication effect methamphetamine provide inform consent time baseline session No diagnosis schizophrenia SCID . If history mood anxiety disorder , active pharmacological treatment least previous two week Must suicidal homicidal Not currently take psychotropics ( antipsychotic , mood stabilizing , antianxiety , antidepressant medication ) Female subject must pregnant lactating , must use approved birth control method child bear potential No medical contraindication ( recent myocardial infarction , cerebrovascular accident , abnormal lab value 3 x normal range ) No unstable diabetes current fast blood glucose test &gt; 140 mg/dl No diagnosis dementia Must stable address access telephone Inability unwillingness provide consent Medical psychiatric instability , require inpatient treatment Previous report allergic adverse reaction aripiprazole Being involuntary commitment in/outpatient psychiatric treatment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Methamphetamine</keyword>
	<keyword>Therapeutics</keyword>
	<keyword>Psychopharmacology</keyword>
	<keyword>Amphetamine</keyword>
</DOC>